Dabrafenib mesylate (Tafinlar) has been approved in Germany since August 2013 for the treatment of patients with advanced melanoma. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German IQWiG examined whether dabrafenib offers an added benefit over the appropriate comparator therapy. According to the findings, an added benefit of dabrafenib is not proven: Regarding mortality, symptoms, health-related quality of life and treatment discontinuation due to side effects, no advantage can be derived from the dossier. Concerning other side effects, the data were too uncertain to allow drawing any conclusions.

For more details, go to: https://www.iqwig.de/en/press/press_releases/press_releases/dabrafenib_in_melanoma_added_benefit_not_proven.5365.html